Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
about
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesAdoptive T-Cell ImmunotherapyPreventing stem cell transplantation-associated viral infections using T-cell therapyT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectT lymphocytes targeting native receptorsEpstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplantMonitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantationNovel immunotherapies for hematologic malignanciesAntiviral T-cell therapyAdoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized miceThe European Hematology Association Roadmap for European Hematology Research: a consensus documentAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesEstablishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.Toward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.Gene and cell therapy for children--new medicines, new challenges?Controlling cytomegalovirus: helping the immune system take the leadImmunotherapy: opportunities, risks and future perspectivesAdenovirus infections in immunocompetent and immunocompromised patients.Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Pediatric lymphomas and histiocytic disorders of childhoodBuilding and optimizing a virus-specific T cell receptor library for targeted immunotherapy in viral infections.Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application.Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2.Human adenovirus-specific γ/δ and CD8+ T cells generated by T-cell receptor transfection to treat adenovirus infection after allogeneic stem cell transplantation.The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodBlood and marrow transplant clinical trials network state of the Science Symposium 2014Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation PracticesDefinition and characterization of novel HLA-*A02-restricted CD8+ T cell epitopes derived from JCV polyomavirus with clinical relevance.Genetically modified T-cell therapy for osteosarcomaChallenges and opportunities of allogeneic donor-derived CAR T cellsReprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells.
P2860
Q26745838-F113DFA5-A682-4124-8E21-FA687E23DE44Q26782845-D2E657F5-37C8-417D-9AAC-7C8F9E50E23AQ26801365-FDE4C435-797B-4E02-A0E7-A6E4591B6B60Q26826830-278CD656-11E7-4059-9144-86B1F48A422EQ26853345-1AA95B2A-1442-48B5-8F89-F1B08FFE93FBQ26861623-52442F5C-7F40-4F2E-AB50-DCA00CD7230DQ26861648-817B2D41-D2FC-4AE3-8625-697D69F7357AQ27004436-B74DD1B3-246B-46FD-8D31-C18407FFBAD8Q27028006-1F1B0C19-7AB1-4AF0-A260-BD75751B515FQ27324235-1259B2A5-6EBC-48C1-9999-D22BA3C3A2FCQ28830861-351C0272-A1C3-4471-991F-AB442C2998FCQ29393780-90432102-875A-4AFE-BC8E-94AB51C3DF25Q33456742-8F5F82A5-158C-481C-AB19-374F7451BD92Q33633262-8B834655-A93A-4107-8CEC-4B4D0548E118Q33647028-7DAF8232-2C0E-429C-8608-6767B185DD61Q33724261-D3919E4B-C8AD-444E-B5B9-BBF838D5CD19Q33734872-1B59AB4E-008D-446C-A554-9EF8441DDFC3Q33819841-3A753B2A-5C28-4841-9931-87EE787A60A5Q33820695-84CE62DA-81E2-40BB-ACFD-F90AB15DF91CQ33941012-EB4725B4-1486-4CD8-A8BA-F93A4F1BB62EQ34057627-E35B31D6-2631-4BE0-B52F-46E68FB256E0Q34273968-FDCE38A5-A7FF-44E3-97AF-F183CF53F730Q34605894-446690EB-814F-4977-B3C9-4A54D567B0BFQ35102451-300DD610-5448-48F5-B106-9CD3D81EDE23Q35104509-244DC689-5146-49E6-B0A6-A5EF2D60412DQ35136456-1D7D18CE-2233-4FF4-ADBE-CA51667D4553Q35156297-C3CF5F8C-8713-4C04-B535-E54D1090D574Q35308252-C5FBE5B2-60E8-411E-B9B1-74900A2C6593Q35477534-0DA715A2-F486-4C18-BD8D-4A169D25A6E7Q35514288-C7FBD045-A26F-4BF6-94EF-B83CADE025A9Q35582326-62332278-47FC-462F-BA69-BB3725143ACAQ35591760-E3AA5AA7-674B-43E5-8F4A-E8D67D253FD7Q35653249-2A4DE93F-CA42-4C94-BB63-689C590D8B58Q35776868-15745A1B-6E50-48B4-BEA8-247C487147FBQ35958223-CE02DA4D-4F01-4ADD-BB3E-81152DCF95B4Q35975542-20CB3E46-9BB5-4C9F-9B69-33E18F9EF53FQ36153492-9241AA1F-BA22-4362-8B54-6C66633CEF04Q36198232-88629090-80A3-4AE4-BA6F-F9BE1BB35951Q36257036-648E252D-A833-434C-9751-2B446E0EFAB3Q36448423-210223F4-4C89-4914-B8F6-92BC68193B25
P2860
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Multicenter study of banked th ...... etic stem cell transplantation
@en
type
label
Multicenter study of banked th ...... etic stem cell transplantation
@en
prefLabel
Multicenter study of banked th ...... etic stem cell transplantation
@en
P2093
P2860
P1433
P1476
Multicenter study of banked th ...... etic stem cell transplantation
@en
P2093
Adam M Mendizabal
Adrian P Gee
Ann M Leen
Bambi J Grilley
Bimalangshu R Dey
Catherine M Bollard
Cliona M Rooney
Elizabeth J Shpall
Helen E Heslop
Joseph H Antin
P2860
P304
P356
10.1182/BLOOD-2013-02-486324
P407
P577
2013-04-22T00:00:00Z